Gaurav Bajaj

4PUBLICATIONS
41CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Kristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem

|May 10, 2025
Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data.

Gaurav Bajaj, Dmitry Shchelokov, Oleg Demin

|May 30, 2019
Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.

Gaurav Bajaj, Satyendra Suryawanshi, Amit Roy

|May 16, 2019
Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance.

Lora Hamuro, Paul Statkevich, Akintunde Bello

Pageof 1